| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on termination of operating lease | NaN | NaN | NaN | 12,262 |
| Net income | 1,985,635 | 1,686,040 | 1,819,529 | 6,978,127 |
| Depreciation and amortization | 95,414 | 223,930 | 243,746 | 1,251,514 |
| Amortization of operating right of use asset | 0 | 0 | 0 | 63,597 |
| Stock compensation expense | 70,013 | 156,033 | 101,023 | 403,783 |
| Bad debt expense | 225,000 | 225,000 | 225,000 | 600,000 |
| Accounts receivables | 445,070 | 978,753 | 245,439 | 1,301,304 |
| Operating right of use asset | NaN | NaN | NaN | -186,709 |
| Long-term receivables, prepaids and other assets | 236,503 | 260,726 | 265,761 | 447,479 |
| Accounts payable | 80,949 | -120,400 | 27,480 | 17,060 |
| Operating lease liability | 0 | 0 | 0 | -250,786 |
| Accrued liabilities | 199,798 | 346,778 | 122,580 | 196,499 |
| Deferred revenue | 108,230 | 960,323 | -489,711 | 734,674 |
| Net cash provided by operating activities | 2,083,466 | 2,238,225 | 1,538,447 | 8,420,132 |
| Issuance of note receivable | 3,000,000 | NaN | NaN | NaN |
| Purchase of property and equipment | 0 | -1 | 11,750 | 15,965 |
| Sale (purchase) of marketable securities | -31,328 | 20 | -8,609 | 16,134 |
| Net cash provided by (used in) investing activities | -3,031,328 | 21 | -20,359 | 169 |
| Common stock buyback/retirement | 549,944 | 1,098,608 | 149,985 | 200,035 |
| Redemption of series b-1 preferred | NaN | NaN | NaN | 2,999,970 |
| Redemption of series b preferred | 375,003 | 749,995 | 749,995 | NaN |
| Proceeds from exercise of warrants | 0 | 0 | NaN | 79,120 |
| Proceeds from employee stock plan | 41,040 | 0 | 63,479 | 134,346 |
| Dividends paid | 410,785 | 424,495 | 402,917 | 1,656,377 |
| Payments on notes payable and capital leases | 54,381 | 53,461 | 52,669 | 362,442 |
| Net cash used in financing activities | -1,349,073 | -2,326,559 | -1,292,087 | -5,005,358 |
| Net increase (decrease) in cash and cash equivalents | -2,296,935 | -88,313 | 226,001 | 3,414,943 |
| Cash and cash equivalents at beginning of period | 28,706,493 | 28,794,806 | 28,568,805 | 25,153,862 |
| Cash and cash equivalents at end of period | 26,409,558 | 28,706,493 | 28,794,806 | 28,568,805 |
ReposiTrak, Inc. (TRAK)
ReposiTrak, Inc. (TRAK)